共 50 条
- [41] Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteersBMC Pharmacology and Toxicology, 18Gurudatt ChandorkarQiao ZhanJulie DonovanShruta RegeHernando Patino
- [42] Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteersBMC PHARMACOLOGY & TOXICOLOGY, 2017, 18Chandorkar, GurudattZhan, QiaoDonovan, JulieRege, ShrutaPatino, Hernando
- [43] Phase 1/2, Open-Label, Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ701 in Adults with ENPP1 DeficiencyJOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 376 - 377Sabbagh, YvesWermers, RobertFuhr, RainardSchnabel, DirkArnason, TerraBesancon, AlixCizman, BorutWenkert, DeborahGunter, Kurt
- [44] Phase 1 study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United StatesEJC SUPPLEMENTS, 2008, 6 (12): : 90 - 91Infante, J.Dees, E. C.Cohen, R. B.Burris, H.O'Neil, B.Murphy, P.Lee, Y.Pappas, J.Ecsedy, J. A.Eton, O.
- [45] Pharmacokinetics of Fentanyl Sublingual Spray in Opioid-Naïve Participants: Results of a Phase 1, Multiple Ascending Dose StudyClinical Drug Investigation, 2018, 38 : 715 - 726Richard L. RauckD. Alexander OhNeil SinglaChristian KochNeha ParikhSrinivas NalamachuJin YuSteven James
- [46] Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics - results from single oral dose studies in healthy volunteersBRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (05) : 1240 - 1254Stoch, S. AubreyZajic, StefanStone, Julie A.Miller, Deborah L.van Bortel, LucasLasseter, Kenneth C.Pramanik, BarnaliCilissen, CarolineLiu, QiLiu, LidaScott, Boyd B.Panebianco, DeborahDing, YuGottesdiener, KeithWagner, John A.
- [47] A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB InhibitorJOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (12): : 1557 - 1565Dennie, JustinVandell, Alexander G.Inoue, SatoshiGajee, RoohiPav, JosephZhang, GeorgeZamora, CynthiaMasuda, NobuhisaUchiyama, MinoruYamada, MakikoSenaldi, Giorgio
- [48] Pharmacokinetics of Fentanyl Sublingual Spray in Opioid-Na⟨ve Participants: Results of a Phase 1, Multiple Ascending Dose StudyCLINICAL DRUG INVESTIGATION, 2018, 38 (08) : 715 - 726Rauck, Richard L.Oh, D. AlexanderSingla, NeilKoch, ChristianParikh, NehaNalamachu, SrinivasYu, JinJames, Steven
- [49] A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignanciesTHERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14Ho, JingshanHeong, ValerieYong, Wei PengSoo, RossChee, Cheng EanWong, AndreaSundar, RaghavThian, Yee LiangGopinathan, AnilPang, Mei YanKoe, PriscilliaJeraj, Santhiay NathanSoe, Phyu PyarSoe, Mu YarTang, TiffanyNg, Matthew C. H.Tai, David W. M.Tan, Tira J. Y.Xu, HongmeiChang, HuaLandesman, YosefShah, JatinShacham, SharonLee, Soo ChinTan, Daniel S. W.Goh, Boon CherTan, David S. P.
- [50] Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy SubjectsClinical Pharmacokinetics, 2006, 45 : 821 - 841Reza KhosravanBrian A. GrabowskiJing-Tao WuNancy Joseph-RidgeLaurent Vernillet